Welcome to our dedicated page for Tiziana Life Sciences Com SEC filings (Ticker: TLSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tiziana Life Sciences Ltd. filings document foreign-private-issuer material-event disclosures for a clinical-stage biotechnology company developing intranasal foralumab, a fully human anti-CD3 monoclonal antibody. The company’s Form 6-K reports furnish press-release exhibits on clinical and preclinical data, biomarker findings, peer-reviewed study publications, conference presentations, and program activity in neuroinflammatory and neurodegenerative diseases.
The filing record also includes capital-structure disclosures tied to registered direct offerings of ordinary shares and warrants, together with governance and security-structure information relevant to the company’s Nasdaq-listed ordinary shares and foreign issuer reporting framework.
Tiziana Life Sciences LTD filed a report stating that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS), held September 24–26, 2025 in Barcelona, Spain. ECTRIMS is described as the world’s largest annual international conference focused on basic and clinical research in multiple sclerosis, bringing together leading scientists, clinicians, and industry partners.
The company’s press release with further details is furnished as Exhibit 99.1 to this report and is not incorporated by reference into other securities filings unless specifically referenced.
Tiziana Life Sciences LTD reported that the U.S. Department of Defense has awarded a research grant to study its intranasal anti-CD3 therapy in traumatic spinal cord injury. This program aims to evaluate whether the company’s intranasal anti-CD3 platform, previously focused on autoimmune and neuroinflammatory diseases, can be applied to severe neurological trauma such as spinal cord injury. The grant supports Tiziana’s strategy to expand this platform into larger, underserved neurological indications, potentially broadening the future scope of its therapeutic pipeline.
Tiziana Life Sciences LTD filed a Form 6-K to report that Chief Executive Officer Ivor Elrifi purchased 14,848 shares of Tiziana common stock in the open market at $1.65 per share on September 9, 2025. This transaction increases his total purchased shareholding to 193,848 shares.
The filing also notes that this purchase updates and corrects an earlier press release issued the same day, and includes the related press release as an exhibit.
Tiziana Life Sciences LTD reported that its Chief Executive Officer, Ivor Elrifi, purchased 193,848 shares of Tiziana common stock in the open market. The shares were bought at a price of $1.65 per share, indicating a direct increase in the CEO’s personal ownership stake. This transaction was disclosed in a Form 6-K, with additional details provided in a press release attached as an exhibit.
On September 5, 2025, Tiziana Life Sciences LTD reported that its Executive Chairman and Founder, Gabriele Cerrone, purchased 25,000 common shares at $1.60 per share. This transaction increased his total holding to 43,277,143 common shares, representing 36.28% of the company’s issued share capital. The move signals a larger personal stake by the company’s top insider, aligning his interests more closely with other shareholders.
Tiziana Life Sciences reported that the first participant has been enrolled and dosed in its Phase 2a clinical trial evaluating intranasal foralumab in patients with Multiple System Atrophy (MSA) at Brigham and Women's Hospital in Boston. The Form 6-K furnishes a press release as Exhibit 99.1 and states the exhibit is being furnished, not filed, under applicable securities rules. The disclosure provides the enrollment and site details only and does not include trial results, enrollment targets, dosing schedules, safety data, or timelines.
Tiziana Life Sciences reported that the U.S. Food and Drug Administration has approved an Investigational New Drug (IND) application for a Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA).
The company states MSA is an unmet medical need with no FDA-approved therapies and is described as an orphan-designated disease. The announcement is furnished as Exhibit 99.1 to this Form 6-K.